Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen caught up with Proactive London's Andrew Scott soon after announcing they've amended the protocol for a second phase III study of its drug for acute respiratory distress syndrome (ARDS).
The tweak's in response to input from the US FDA.
Dr Jalkanen says following the meeting with regulators their treatment of patients with its interferon-beta (IFN-beta) medication will exclude the overlapping use of steroids.